EUVIMEDEUVIMED entdecken
Crossref

MAPK-Dependent Anticancer Effects of YK-4-279 in Osteosarcoma: Cell Cycle Arrest, DNA Damage, and Apoptosis

Lucas Meyer, Anna Schmid, Stefan Braun

Pharmaceutical Sciences and Drug Design · 2026 · 6 (1) · 39-56

DOI: 10.51847/zyrefzzlfr ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2026. Verfasst von Lucas Meyer und 2 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

YK-4-279 is an emerging anticancer compound that has demonstrated activity across a range of tumor models. Osteosarcoma (OS), a highly aggressive bone malignancy predominantly diagnosed in adolescents, still lacks satisfactory therapeutic options. A detailed investigation of how YK-4-279 functions in OS is essential for determining its potential clinical relevance. Therefore, the present study aimed to evaluate its effects on OS cell viability, proliferation, DNA damage, cell cycle regulation, a

Zitieren

APA

Meyer, L., Schmid, A., & Braun, S. (2026). MAPK-Dependent Anticancer Effects of YK-4-279 in Osteosarcoma: Cell Cycle Arrest, DNA Damage, and Apoptosis. Pharmaceutical Sciences and Drug Design, 6(1), 39-56. https://doi.org/10.51847/zyrefzzlfr

Vancouver

Meyer L, Schmid A, Braun S. MAPK-Dependent Anticancer Effects of YK-4-279 in Osteosarcoma: Cell Cycle Arrest, DNA Damage, and Apoptosis. Pharmaceutical Sciences and Drug Design. 2026;6(1):39-56. doi:10.51847/zyrefzzlfr

BibTeX
@article{Meyer2026,
  author = {Meyer, Lucas and Schmid, Anna and Braun, Stefan},
  title = {MAPK-Dependent Anticancer Effects of YK-4-279 in Osteosarcoma: Cell Cycle Arrest, DNA Damage, and Apoptosis},
  journal = {Pharmaceutical Sciences and Drug Design},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {39--56},
  doi = {10.51847/zyrefzzlfr}
}
Kostenlos starten →